Effects of ACE inhibitor and β-adrenergic blocker on plasma NPY and NPY receptors in aortic vascular smooth muscle cells from SHR and WKY rats

Neuropeptides

Volumn 36, Issue 5, 2002, Pages 353-361

  Zeng, Chunyu ^a,b   Wang, Xukai ^a   Liu, Guangyao ^a   Yang, Chengming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; PERIDOPRIL; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; AORTA WALL; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SMOOTH MUSCLE FIBER;

EID: 0036815816     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(02)00087-2     Document Type: Article

References (57)

1. Aihara H, Ogawa H, Kasuya A, Yoshida M, Suzuki-Kusaba M, Hisa H, Satoh S (1999) Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats. Eur J Pharmacol 373: 35-40.
2. Agnati LF, Fuxe K, Benfenati F, Battistini N, Harfstrand A, Tatemoto K, Hokfelt T, Mutt V (1983) Neuropeptide Y in vitro selectivity increases the number of α2-adrenergic binding sites in membranes of the medulla oblongata of the rat. Acta Physiol Scand 118: 293-295.
3. Balasubramaniam A, Sheriff S, Rigel DF, Fischer JE (1990) Characterization of neuropeptide Y binding sites in rat cardiac ventricular membranes. Peptides 11: 545-550.
4. Begum N, Song Y, Rienzie J, Ragolia L (1998) Vascular smooth muscle cell growth and insulin regulation of mitogen-activated protein kinase in hypertension. Am J Physiol 275: C42-C49.
5. Bohm M, Zolk O, Flesch M, Schiffer F, Schnabel P, Stasch JP, Knorr A (1998) Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac β-adrenergic signal transduction. Hypertension 31: 747-754.
6. Braam B, Mitchell KD, Fox J, Navar LG (1993) Proximal tubular secretion of angiotensin II in rats. Am J Physiol 264: F891-F898.
7. Dahlof P, Tarizzo VI, Lundberg JM, Dahlof C (1991a) α- and α-adrenoceptor-mediated effects on nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig. J Auton Nerv Syst 35: 199-210.
8. Dahlof P, Lundberg JM, Dahlof C (1991b) Effect of captopril on plasma levels of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea pig. Neuropeptides 18: 171-180.
9. Devlin AM, Gordon JF, Davidson AO, Clark JS, Hamilton CA, Morton JJ, Campbell AM, Reid JL, Dominiczak AF (1995) The effects of perindopril on vascular smooth muscle polyploidy in stroke-prone spontaneously hypertensive rats. J Hypertens 13: 211-218.
10. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ (1991) Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60: 653-688.
11. Edling O, Bao G, Feelisch M, Unger T, Gohlke P (1995) Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther 275: 854-863.
12. Fan XM, Hendley ED, Forehand CJ (1995) Enhanced vascular neuropeptide Y-immunoreactive innervation in two hypertensive rat strains. Hypertension 26: 758-763.
13. Fox J, Guan S, Hymel AA, Navar LG (1992) Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 262: F902-F909.
14. Golomb E, Hill MR, Brown RG, Keiser HR (1994) Ouabain enhances the mitogenic effect of serum in vascular smooth muscle cells. Am J Hypertens 7: 69-74.
15. Gray TS, Morley JE (1986) Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous system. Life Sci 38: 389-401.
16. Han S, Yang CL, Chen X, Naes L, Cox BF, Westfall T (1998) Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol 274: H290-H294.
17. Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J 4: 2881-2889.
18. Howe PR, Rogers PF, Morris MJ, Chalmers JP, Smith RM (1986) Plasma catecholamines and neuropeptide-Y as indices of sympathetic nerve activity in normotensive and stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 8: 1113-1121.
19. Katsuya T, Higaki J, Zhao Y, Mild T, Mikami H, Serikawa T, Ogihara T (1993) A neuropeptide Y locus on chromosome 4 cosegregates with blood pressure in the spontaneously hypertensive rat. Biochem Biophys Res Commun 192: 261-267.
20. Khatun S, Kanayama N, Belayet HM, Bhuiyan AB, Jahan S, Begum A, Kobayashi T, Terao T (2000) Increased concentrations of plasma neuropeptide Y in patients with eclampsia and preeclampsia. Am J Obstet Gynecol 182: 896-900.
21. Latini R, Masson S, Jeremic G, Luvara G, Fiordaliso F, Calvillo L, Bernasconi R, Torri M, Rondelli I, Razzetti R, Bongrani S (1998) Comparative efficacy of a DA2/alpha2 agonist and a β-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 31: 601-608.
22. Lee RM, Lu M, Gillies L, Werstiuk ES (1997) Antihypertensive effects of perindopril treatment in adult spontaneously hypertensive rats. Can J Cardiol 13: 831-835.
23. Lundberg JM (1996) Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48: 113-178.
24. Majewski H, Hedler L, Schurr C, Starke K (1984) Modulation of noradrenaline release in the pithed rabbit: A role for angiotensin II. J Cardiovasc Pharmacol 6: 888-896.
25. Makino N, Sugano M, Ohtsuka S, Sawada S, Hata T (1999) Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats. Cardiovasc Res 44: 543-548.
26. Massfelder T, Taesch N, Endlich N, Eichinger A, Escande B, Endlich K, Barthelmebs M, Helwig JJ (2001) Paradoxical actions of exogenous and endogenous parathyroid hormone-related protein on renal vascular smooth muscle cell proliferation: Reversion in the SHR model of genetic hypertension. FASEB J 15: 707-718.
27. 1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusion. J Cardiovasc Pharmacol 34: 321-326.
28. 2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol 336: 257-265.
29. McDermott BJ, Millar BC, Piper HM (1993) Cardiovascular effects of neuropeptide Y: Receptor interactions and cellular mechanisms. Cardiovasc Res 27: 893-905.
30. 2+. Biochem Int 22: 205-212.
31. Millar BC, Weis T, Piper HM et al. (1991) Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes. Am J Physiol 261: H1727-H1733.
32. Mills PJ, Dimsdale JE, Ziegler MG, Hauger RL, Nelesen RA, Brown MR (1993) Sympathetic alterations after sodium restriction and short-term captopril administration. J Am Coll Cardiol 21: 177-181.
33. 1-receptor mRNA. Neuropeptides 33: 253-259.
34. Mullins D, Kirby D, Hwa J et al. (2001) Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol 60: 534-540.
35. 2 receptor-mediated stimulation of mitogen-activated protein kinase activity. Regul Pept 75-76: 207-213.
36. Ogawa T, Kitamura K, Kawamoto M, Eto T, Tanaka K (1989) Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR). Biochem Biophys Res Commun 165: 1399-1405.
37. Paran E, Neumann L, Cristal N (1992) Effects of mental and physical stress on plasma catecholamine levels before and after β-adrenoceptor blocker treatment. Eur J Clin Pharmacol 43: 11-15.
38. 1 receptor. Nat Med 4: 722-726.
39. 2 receptors. Am J Physiol 277: H940-H946.
40. Rosen SG, Supiano MA, Perry TJ, Linares OA, Hogikyan RV, Smith MJ, Halter JB (1990) β-adrenergic blockade decreases norepinephrine release in humans. Am J Physiol 258: E999-E1005.
41. Rutan GH, Feig PU, May S, Kriegman AG, Brady EM (1993) A comparison of once-daily atenolol and metoprolol using office and ambulatory blood pressure monitoring. J Clin Pharmacol 33: 418-426.
42. 2-type receptors for peptide YY on renal proximal tubular cells in the rabbit. Am J Physiol 257: F978-F984.
43. Shigeri Y, Fujimoto M (1993) Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 149: 19-22.
44. Sbirrazzuoli V, Drici M, Garraffo R, Candito M, Gibelin P, Morand P, Lapalus P (1989) Changes in lymphocyte β-adrenoceptor density after dilevalol oral treatment. Drugs Exp Clin Res 15: 223-229.
45. Smith KA (1984) Interleukin 2. Annu Rev Immunol 2: 319-333.
46. 1-adrenergic chronotropic response in neuropeptide Y-treated cardiomyocytes. Eur J Pharmacol 349: 377-381.
47. Tatemoto K (1982) Neuropeptide Y: Complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 79: 5485-5489.
48. 2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides 25: 289-298.
49. Tsunoda M, Takezawa K, Santa T, Ina Y, Nagashima K, Ohmori K, Kobayashi S, Imai K (2000) New approach for measurement of sympathetic nervous abnormality in conscious, spontaneously hypertensive rats. Jpn J Pharmacol 83: 39-45.
50. Wahlestedt C, Hakanson R, Vaz CA, Zukowska-Grojec Z (1990) Norepinephrine and neuropeptide Y: Vasoconstrictor cooperation in vivo and in vitro. Am J Physiol 258: R736-R472.
51. Westfall TC, Chen XL, Ciarleglio A, Henderson K, Del Valle K, Curfman-Falvey M, Naes L (1990a) In vitro effects of neuropeptide Y at the vascular neuroeffector junction. Ann N Y Acad Sci 611: 145-155.
52. Westfall TC, Han SP, Chen XL, Del Valle K, Curfman M, Ciarleglio A, Naes L (1990b) Presynaptic peptide receptors and hypertension. Ann N Y Acad Sci 604: 372-388.
53. Woo ND, Ganguly PK (1995) Neuropeptide Y prevents agonist-stimulated increases in contractility. Hypertension 26: 480-484.
54. Zeng C, Liu G, Wang X, Sun J, Cheng S (1997a) The immunoassay for neuropeptide Y and its clinical application. Chin J Nucl Med 17: 181-182.
55. Zeng C, Liu G, Wang X, Sun J, Cheng S (1997b) Determination of neuropeptide Y receptor in vascular smooth cells from spontaneously hypertensive rats. Chin J Nucl Med 17: 207-208.
56. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H (1998) Mechanisms of vascular growth-promoting effects of neuropeptide Y: Role of its inducible receptors. Regul Pept 75-76: 231-238.
57. Zukowska-Grojec Z, Haass M, Bayorh MA (1986) Neuropeptide Y and peptide YY mediate nonadrenergic vasoconstriction and modulate sympathetic responses in rats. Regul Pept 15: 99-110.